Asymptomatic syndrome of polycythemic hyperviscosity: effect of partial plasma exchange transfusion

https://doi.org/10.1016/S0022-3476(05)82487-4Get rights and content

We determined the cerebral hemodynamic changes in infants with asymptomatic polycythemic hyperviscosity syndrome and whether treatment with partial plasma exchange transfusion (PPET) would affect hemodynamics as well as outcome. From a routine cord blood hematocrit screening, 71 babies were identified as needing to be tested for polycythemic hyperviscosity. In addition to clinical evaluation, each infant had radial artery hematocrit and viscosity determinations, blood gas determinations, cerebral blood flow velocity studies, cranial ultrasonography, and noninvasive intracranial pressure determination. Bables with symptomatic hyperviscosity (n=17) were treated by PPET, whereas those with asymptomatic hyperviscosity (n=28) were randomly selected to have PPET (n=14) or to be observed (n=14). The remaining babies (n=26) with normal viscosity served as control subjects. Both hematocrit and viscosity decreased after PPET but remained unchanged in babies with hyperviscosity who were merely observed. Reversal of cerebral blood flow velocity abnormalities was observed after PPET in the infants with symptomatic hyperviscosity, whereas those who had no symptoms had normal results on Doppler studies at the outset, and no significant changes occurred with either PPET or observation. There were two deaths in the group with symptoms. A total of 46 babies returned for follow-up evaluation at a mean age of 30±7.7 months. Outcome of the control group was no better than that of those who had hyperviscosity, and outcomes did not differ between the babies with symptomatic and those with asymptomatic hyperviscosity, nor between those treated with PPET and those who were only observed. Multivariate analysis revealed that other perinatal risk factors and race, rather than polycythemia or PPET, significantly influenced long-term outcome.

References (20)

There are more references available in the full text version of this article.

Cited by (45)

  • Neonatal Erythrocyte Disorders

    2023, Avery's Diseases of the Newborn
  • Stroke in the Newborn

    2018, Volpe's Neurology of the Newborn
  • Neonatal polycythemia and hyperviscosity

    2008, Seminars in Fetal and Neonatal Medicine
    Citation Excerpt :

    There is no evidence of lasting cardiopulmonary complications from neonatal polycythemia. Cyanosis, tachypnea, cardiomegaly, pulmonary vascular congestion, pleural effusions, and pulmonary hypertension are due to elevated pulmonary vascular resistance and increased intrapulmonary shunting secondary to increased blood viscosity.32 Murphy et al. demonstrated elevated right ventricular pre-ejection to right ventricular ejection time ratios in 19 asymptomatic polycythemic infants.

  • Retinopathy associated with hyperviscocity syndrome

    2021, International Journal of Current Research and Review
View all citing articles on Scopus
View full text